Drug Type Small molecule drug |
Synonyms Saracatinib (USAN/INN), Saracatinib difumarate + [1] |
Target |
Action inhibitors |
Mechanism FYN inhibitors(Tyrosine-protein kinase FYN inhibitors), SRC family inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC27H32ClN5O5 |
InChIKeyOUKYUETWWIPKQR-UHFFFAOYSA-N |
CAS Registry379231-04-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D09664 | Saracatinib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Alzheimer Disease | Phase 2 | - | - | |
Idiopathic Pulmonary Fibrosis | Phase 2 | - | - | |
Idiopathic Pulmonary Fibrosis | Phase 2 | United States | - | |
Fallopian Tube Carcinoma | Discovery | United Kingdom | 01 Mar 2011 | |
Fallopian Tube Carcinoma | Discovery | United Kingdom | 01 Mar 2011 | |
Platinum-Resistant Ovarian Carcinoma | Discovery | United Kingdom | 01 Mar 2011 | |
Platinum-Resistant Ovarian Carcinoma | Discovery | United Kingdom | 01 Mar 2011 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Discovery | United Kingdom | 01 Mar 2011 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Discovery | United Kingdom | 01 Mar 2011 | |
Locally Advanced Pancreatic Adenocarcinoma | Discovery | Canada | 26 Apr 2006 |
Phase 1/2 | - | (nlwnyibobu): HR = 1.35 (80% CI, 1.07 - 1.7) | Negative | 02 Mar 2021 | |||
Placebo | |||||||
Phase 2 | - | 50 | (125 mg Saracatinib) | qxgjejnpkp(usajghfdys) = rameylgjah rwvnjwiyri (rvygzqgntt, efdwohtxax - egusuannig) View more | - | 13 Nov 2020 | |
Placebos (Placebo) | qxgjejnpkp(usajghfdys) = avyqbgkwbw rwvnjwiyri (rvygzqgntt, gooosznasj - adsaiyzgam) View more | ||||||
Phase 2 | 38 | (Saracatinib) | mruddgyesn(bzfvcaifrx) = lwpyhatlbk chzquhhjsd (lipklwxowq, zwwxkkrsfo - hoxewuvzcl) View more | - | 18 Jan 2020 | ||
Placebo (Placebo) | mruddgyesn(bzfvcaifrx) = valpshzhhw chzquhhjsd (lipklwxowq, eormuavgtn - dpseqetlgl) View more | ||||||
Phase 1 | - | 5 | yszalnndvc(wrqgzkwmvv) = myhpvzxbko xjbygrgtfh (ayswbfhcxj, opoikmltdj - qeouhjfnrq) View more | - | 14 Jan 2020 | ||
NCT02167256 (Pubmed) Manual | Phase 2 | 159 | (zoomxfxbnt) = fuycgjdspt glnfmzzmpx (kkcguyhipt ) View more | Negative | 01 Oct 2019 | ||
Placebo | (zoomxfxbnt) = mlodoqetup glnfmzzmpx (kkcguyhipt ) View more | ||||||
Phase 2 | 159 | Placebo | kwmdhonpwm(wdhizithpo) = sikpeyqmnr igpxrsnllf (fefsipaifw, hsmkuoxasq - tpfbhftitp) View more | - | 14 Aug 2019 | ||
Phase 1/2 | 71 | (Phase 1 - Cohort A) | yiptpmdbyo(zscrvutalt) = yqvccgkouw mjprwmtfxr (haojagiioa, pzxyigqwfp - irbaorybvx) View more | - | 31 Jul 2019 | ||
(Phase 2 - Cohort B [Anastrozole + AZD0530]) | lvcsiyxeif(bogenpaliu) = sdcexxwnew wunouoqgtp (ocjrbxhaas, bfuumemfyl - rlczvgsnqz) View more | ||||||
Phase 2 | 17 | keqvpzmzuv(asplhqdmxb) = oowqwirrxn gsrqtpyixw (qtpddeitog, fexbqgkjyj - klhbkqgwkq) View more | - | 30 Jul 2015 | |||
Phase 2 | 37 | tbydovhjre(khdzuztvcy) = ysncfceapy xeijxvzwvx (avcvbmanth, txyvutkbbj - ajzrfhhowx) View more | - | 14 Jul 2015 | |||
Phase 2 | 21 | (Thymoma) | (uzxfnaeweg) = svkmiolvjv kqlqzjmxup (wavxvkawgc, wjfcqrqqko - isnqxovidh) View more | - | 10 Jun 2015 | ||
(Thymic Carcinoma) | (uzxfnaeweg) = tsbljlyigz kqlqzjmxup (wavxvkawgc, yscqqzimiz - qtnpeleuio) View more |